ding at —12x our 2014 EPS estimate, particularly given Cigna's below- average exposure to the 2014 healthcare reform uncertainty. Valuation We rate Cigna Overweight. Our YE 2014 price target of $95 is based on a target PIE of 12x our 2015 EPS estimate. Cigna has historically traded at a discount to the group, b